|
|
Merknamen in verschillende landen |
|
|
Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant
|
Eberelbin |
Iran |
Eunexon |
Peru |
Eurovinorelbin |
Duitsland |
Navelbin |
Hongarije |
Navelbine |
Argentinië, Australië, België, Chili, Colombia, Denemarken, Duitsland, Egypte, Finland, Frankrijk, Griekenland, Groot Britannië, Ierland, IJsland, Indië, Iran, Italië, Luxemburg, Maleisië, Mexico, nieuw Zeeland, Noorwegen, Oostenrijk, Peru, Polen, Portugal, Roemenië, Saudi-Arabië, Spanje, Tunisie, Turkije, USA, Verenigde Arabische Emiraten, Zweden, Zwitserland |
Navildez |
Mexico |
Navin |
Duitsland |
Navirel |
Duitsland, Noorwegen, Zweden |
Okabine |
Peru |
Relbinalur |
Zweden |
Renovel |
Turkije |
Setroxin |
Mexico |
Sulcoline |
Argentinië |
Tarckorel |
Mexico, Peru |
Vieby |
Mexico |
Viessia |
Colombia, Mexico, Venezuela |
Vilne |
Argentinië, Ecuador, Peru |
Vinarine |
Argentinië, Peru, Venezuela |
Vinelbine |
Maleisië |
Vinilex |
Mexico |
Vinkebir |
Argentinië, Peru |
Vinobina |
Colombia |
Vinobur |
Zweden |
Vinolbin |
Duitsland |
Vinorel |
Argentinië, Peru |
Vinorelbin |
België, Duitsland, Ecuador, IJsland, Noorwegen, Oostenrijk, Roemenië, Zweden, Zwitserland |
Vinorelbina |
Colombia, Ecuador, Mexico, Peru, Roemenië, Spanje |
Vinorelbine |
Argentinië, België, Canada, Groot Britannië, Iran, nieuw Zeeland, USA, Zwitserland |
Vinorgen |
Chili, Peru |
Zinavin |
Colombia |
|
|
|
|
Literatuur : Vinorelbine tartrate |
|
|
type |
publicatie |
84 |
Artikel |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
144 |
Artikel |
Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharm 1991 ; 77: 279-285. |
182 |
Artikel |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
Artikel |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
251 |
Artikel |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
307 |
Artikel |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
905 |
Artikel |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
921 |
Artikel |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
1070 |
Artikel |
Balthasar JP. Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. Am J Health-Syst Pharm 1999 ; 56: 1891. |
1413 |
Artikel |
Lieu CL, Chin A, Gill MA. Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature. Int J Pharm Compound 1999 ; 3: 67-68. |
1423 |
Artikel |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1501 |
Artikel |
Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121. |
1520 |
fabrikant |
Etude de stabilité des médicaments en Ecoflac® B Braun 2001 |
1625 |
Artikel |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1662 |
Artikel |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37. |
2260 |
fabrikant |
Stability of vinorelbin "Ebewe" infusion solutions. Ebewe Pharma 2007 |
3128 |
fabrikant |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013 |
3474 |
fabrikant |
Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009 |
3595 |
fabrikant |
Aciclovir - Summary of Product Characteristics Hospira 2009 |
3641 |
fabrikant |
Vinorelbine (Navelbine®) - Summary of Product Characteristics Pierre Fabre 2011 |
3644 |
fabrikant |
Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010 |
3838 |
fabrikant |
Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007 |
4471 |
fabrikant |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019 |
|
|